EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison

April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie Von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst

SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s725

DOI: 10.25251/24g02225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von April Armstrong und 11 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tralokinumab is a high-affinity interleukin (IL)-13 inhibitor while dupilumab targets the IL-4/IL-13 pathway via inhibition of the IL-4 receptor α. Both are approved for the treatment of moderate-to-severe atopic dermatitis (AD), including on the hands where AD often presents an additional burden and treatment challenges. As no head-to-head studies have been conducted, the 16-week efficacy of tralokinumab and dupilumab were compared in patients with AD with hand involvement in a matching-adjusted indirect comparison (MAIC) based on two phase 3 trials, ADHAND and LIBERTY-AD-HAFT.

Methods

In the ADHAND trial (NCT05958407), adults with moderate-to-severe AD with hand involvement were randomized 2:1 to double-blind treatment with tralokinumab 300 mg or placebo every 2 weeks for 16 weeks. In LIBERTY-AD-HAFT (NCT04417894), adults and adolescents (≥12 years) with moderate-to-severe AD with hand and/or foot involvement were randomized 1:1 to dupilumab 300 mg (200 mg in adolescents with body weight

Zitieren

APA

Armstrong, A., Kircik, L., Metelitsa, A., Warren, R. B., Rodriguez, A., Volc, S., Issa, N., Chovatiya, R., Eyben, R. V., Festini, T., Johansen, P., & Ehst, B. (2026). Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison. SKIN The Journal of Cutaneous Medicine, 10(2), s725. https://doi.org/10.25251/24g02225

Vancouver

Armstrong A, Kircik L, Metelitsa A, Warren RB, Rodriguez A, Volc S, et al. Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s725. doi:10.25251/24g02225

BibTeX
@article{Armstrong2026,
  author = {Armstrong, April and Kircik, Leon and Metelitsa, Andrei and Warren, Richard B and Rodriguez, Adrian and Volc, Sebastian and Issa, Naiem and Chovatiya, Raj and Eyben, Rie Von and Festini, Teodora and Johansen, Pierre and Ehst, Benjamin},
  title = {Tralokinumab versus Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis with Hand Involvement: a Matching-Adjusted Indirect Comparison},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {2},
  pages = {s725},
  doi = {10.25251/24g02225}
}
Kostenlos starten →